A Phase 1/2a Study of BMS-986253 (HuMax-IL8) in Combination With Nivolumab in Advanced Cancers

Trial Profile

A Phase 1/2a Study of BMS-986253 (HuMax-IL8) in Combination With Nivolumab in Advanced Cancers

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Feb 2018

At a glance

  • Drugs HuMax IL8 (Primary) ; Nivolumab
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 13 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 22 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top